Phase II Study of Melanoma Vaccine (NSC #683472/675756, IND #6123) and Low-Dose, Subcutaneous Interleukin-2 in Advanced Melanoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Melanoma vaccine (Primary) ; Interleukin-2
- Indications Malignant melanoma
- Focus Therapeutic Use
- 16 Jan 2013 Biomarkers information updated
- 13 Oct 2005 New trial record.